I'd presume Roche will now spend 9-12mths on pre-clinical trials.
In the case of an active drug lead, in-vitro(test tube) and in-vivo(animal testing) are conducted. If results satisfy Roche, milestone payments would flow and clinical trials(human) will then go ahead.
I'm not sure what trials would be carried out if the peptide is a passive carrier.
Whether PYCs peptide is an active drug lead or a carrier for an active molecule, toxicology tests would show any adverse effects.
Hard to know what has already been done. Would be nice to get more detail.
Numerator: you're more knowledgeable, can you add to this?
ST
I'd presume Roche will now spend 9-12mths on pre-clinical...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.37 |
Change
0.010(0.74%) |
Mkt cap ! $799.0M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.39 | $1.33 | $78.52K | 57.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 2166 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 2480 | 1 |
View Market Depth
| Last trade - 13.32pm 21/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |